MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bjh.18885

Медицинская библиотека · British journal of haematology · 2023

Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.

Stuver Robert, Horwitz Steven M, Advani Ranjana H, Vose Julie M, Lee Hun Ju, Mehta-Shah Neha, Zain Jasmine M, Haverkos Bradley, Lechowicz Mary Jo, Moskowitz Alison J, Pham Luu Q, Leyden Elizabeth, Ansell Stephen M, Lunning Matthew A

Клиническое исследование II фазыСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

There remains no one standard induction for nodal-based peripheral T-cell lymphoma (PTCL). We conducted a phase II study of lenalidomide plus CHOEP as a novel induction strategy. Patients received CHOEP at standard doses in combination with 10 mg of lenalidomide on days 1-10 of a 21-day cycle for six cycles of therapy followed by observation, high-dose therapy with autologous stem cell rescue, or maintenance lenalidomide per provider preference. Among 39 patients evaluable for efficacy, the objective response rate after six cycles was 69%, with complete response in 49%, partial response in 21%, stable disease in 0% and progressive disease in 13%. Thirty-two patients (82%) completed full induction, and seven patients (18%) discontinued for toxicity, primarily hematologic. Any grade hematologic toxicity occurred in over 50% of patients, with grade 3 or 4 febrile neutropenia occurring in 35% of patients despite mandated growth factors. With a median followup of surviving patients of 21.3 months, the estimated 2-year progression-free and overall survival were 55% (95% CI 37%-70%) and 78% (95% CI 59%-89%), respectively. In sum, six cycles of lenalidomide plus CHOEP resulted in a modest response rate primarily due to hematologic toxicity, which prevented all patients from completing planned induction.

Для цитирования: Stuver Robert, Horwitz Steven M, Advani Ranjana H, Vose Julie M, Lee Hun Ju, Mehta-Shah Neha, Zain Jasmine M, Haverkos Bradley, Lechowicz Mary Jo, Moskowitz Alison J, Pham Luu Q, Leyden Elizabeth, Ansell Stephen M, Lunning Matthew A. Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.. British journal of haematology. 2023. DOI: 10.1111/bjh.18885.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.